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Abstract
Background: Papillary Microcarcinoma (PMC) of thyroid is a rare type of differentiated thyroid cancer (DTC), which
according to the World Health Organization measures 1.0 cm or less. The gold standard of treatment of PMC is still
controversy. Our aim was to contribute in resolving the debate on the therapeutic choices of the surgical and adjuvant
I-131 (RAI) treatment in PMC.
Methods: From 2000 to 2012, 326 patients were found to have PMC and were retrospectively reviewed for
clinicopathological characteristics, treatment outcomes and prognostic factors.
Results: Mean age of cohort was 42.6 years (range: 18–76) and the mean tumor size was 0.61 cm ± 0.24; lymph
node involvement was seen in 12.9 % of cases. Median follow up period was 8.05 years (1.62–11.4). Total 23 all
site recurrences (7.13 %) were observed; more observed in patients without I-131 ablation (p <0.0001). Ten year
DFS rates were 89.6 %. Cox regression Model analysis revealed size, histopathologic variants, multifocality,
extrathyroidal extension, lymphovascular space invasion, nodal status, and adjuvant RAI ablation the important
prognostic factors affecting DFS.
Discussion: Despite excellent DFS rates, a small proportion of patients with PMC develop recurrences after treatment.
Adjuvant RAI therapy improves DFS in PMC patients with aggressive histopathologic variants, multifocality, ETE, LVSI,
tumor size (> 0.5 cm) and lymph node involvement. Failure of RAI ablation to decrease risk in N1a/b supports
prophylactic central neck dissection during thyroidectomy, however more trials are warranted.
Conclusion: Adjuvant I-131 ablation following thyroidectomy in PMC patients, particularly with poor prognostic factors
improves DFS rates.
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Background
In Saudi Arabia, the incidence of differentiated thyroid
cancers (DTC) especially papillary thyroid cancers (PTC) is
increasing exponentially over the past years accounting for
more than 10 % of all cancers among females [1, 2]. Higher
rates for identification of PTC in recent years are attributed
to the use of high resolution neck ultrasonography (USG)
and USG-guided fine needle aspiration biopsy (FNAB) [3].
With the use of these high resolution transducers, papillary
microcarcinoma (PMC), i.e. tumor size 1 cm or less can
easily be detected [4, 5]. Patients with PMC have generally
an excellent outlook with use of surgery, radioactive
iodine-131 (RAI) ablation, suppression of thyroid-
stimulating hormone (TSH) secretion with levothyroxine,
with long term disease-free survival (DFS) of 84–97 % [6].
However, still there is much debate regarding the most ap-
propriate treatment of PMC ranging from observation
alone to over-treatment with surgery followed by adju-
vant RAI ablation [7–10].
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In the present study, we aimed to evaluate the different
prognostic factors for DFS in PMC patients in our popula-
tion, and also to determine the DFS in patients with PMC
treated with or without adjuvant RAI ablation following
thyroidectomy.
Methods
After formal approval from the institutional ethical
committee, medical records of 1192 patients with
confirmed papillary thyroid cancers (PTC) who were
treated or followed up in two major referral hospitals of
Riyadh, Saudi Arabia, during the period of July 2000 and
December 2012 were reviewed using computer based
departmental database system. Patients with PMC were
retrieved in following manner;
Definition
PMC was defined according WHO classification system
for thyroid tumors as “PTC is measuring ≤ 1 cm in greatest
dimension” [5].
Demographic, clinicopathological and radiological
variables
Demographic and clinical data including age at the diag-
nosis, gender, and symptomatology were reviewed. A
detailed second review of all histopathological specimens
was performed by experienced histopathologist. Differ-
ent histopathological parameters, including the location
of tumor, tumor size, histopathologic variants, multifocal-
ity, extrathyroidal extension (ETE), lymphovascular space
invasion (LVSI), surgical margin status, and cervical lymph
node status and background thyroid tissue were also
recorded. Data from different imaging modalities, includ-
ing neck ultrasonography, whole body I-131 scintigraphy
(WBS), computed tomography (CT) scan of neck and
chest, flourodeoxyglucose positron emission tomography
(FDG-PET) was collected. Periodic postoperative thyroid
function tests (TFTs), thyroid antibodies and stimulated
thyroglobulin (TG) levels (off thyroxin or thyrotropin-Alfa
injection) were also reviewed. Different treatment modal-
ities, including hemi-thyroidectomy (removal of lobe and
isthmus), total thyroidectomy (removal of entire gland),
neck dissection, adjuvant RAI ablation, different doses
used in millicurie (mCi) and the details of neck irradiation
details (if given) were also reviewed.
The primary endpoint was the disease free survival
(DFS). Secondary points were; the frequency of PMC
and histologic variants, local recurrence free survival
(LRFS), distant metastasis free survival (DMFS) and
overall survival (OS) according to (a) treatment with or
without adjuvant I-131 ablation and (b) according to
primary tumor size (≤0.5 cm vs. > 0.5 cm).
Local recurrence was defined as, clinically or radiologic-
ally detectable recurrences in the thyroid bed or in cervical
lymph nodes on imaging (ultrasonography, WBS and CT-
PET) after evaluating for elevated thyroglobulin (TG) levels.
Distant metastasis was defined as, clinically or radiologically
detectable disease outside the neck on imaging (WBS, CT
imaging and CT-PET) after evaluating for elevated thyro-
globulin (TG) levels. The DFS was defined as, the duration
between the surgery date and the date of documented
disease reappearance/relapse, death from cancer and/or last
follow-up (censored). The OS was defined as, the duration
between the surgery date and the date of patient death or
last follow-up (censored).
Statistical analysis
Chi-square test, Student’s t test, or Fisher exact tests
were used to determine the differences in various clin-
ical variables. Multivariate logistic regression was done
using Cox proportional hazards modeling. Probabilities
of LRFS, DMFS, DFS and OS were shown with the
Kaplan-Meier method and the comparisons for various
survival curves were performed using log rank. All
statistical analyses were performed using the computer
program SPSS version 16.0.
Results
Demographic and clinicopathological features of cohort
Among the 1192 PTC patients in our departmental
database, 377 (31.6 %) patients were found to have
PMC. Fifty one (13.3 %) patients with insufficient data
regarding size, treatment and follow-up period were
excluded. The remaining study cohort (n = 326) con-
sisted of 271 (83.1 %) women and 55 (16.9 %) men; the
median age at diagnosis was 42.6 years ±11.6. The
majority of patients had total thyroidectomy (n = 299,
91.7 %); only 27 (8.3 %) patients underwent lobectomy.
The mean tumor size was 0.61 cm ± 0.24, with 12.9 %
(n = 42) involvement of cervical lymph nodes (level VI
in 34 patients). The predominant histopathologic vari-
ants were, classic (265 patients), follicular (41 patients),
and tall cell (11 patients). Other clinicopathological
features are described in Table 1.
Clinicopathological features and DFS Comparison in PMC
patients treated with and without I-131 ablation
Among 326 patients, 182 (55.8 %) patients were given
adjuvant RAI ablation as shown in Table 1. Major indi-
cations for adjuvant RAI ablation were multifocality
(67.1 %), extra-thyroidal extension (ETE) in 31.3 % of
cases, aggressive histopathologic variants (tall cell, scler-
osing), lymph node metastasis (23.1 %) and distant
metastasis at time of presentation (1.65 %). Primary
tumor size was not a primary indication in our series;
however the observed mean tumor size was bigger in
patients treated with adjuvant RAI ablation (0.72 cm vs.
0.44 cm). RAI ablation doses were as; 30 m-curie (mCi)
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Total patients 326/1192 (27.4 %) 182/326 (55.8) 144/326 (44.2) 0.06
Age (years) 42.6 (18–76) SD ±11.6 43.2 (18–76) SD ± 12.4 41.8 (19–71) SD ± 10.2
≤45 years 201 (61.7) 110 (60.4) 94 (65.3) 0.81
≥45 years 125 (38.3) 72 (39.6) 50 (34.7)
Gender
Female 271 (83.1) 146 (80.2) 125 (86.8) 0.06
Male 55 (16.9) 36 (19.8) 19 (13.2)
Female to male ratio 4.9 4.0 6.5
Type of surgery
Total thyroidectomy 299 (91.7) 182 (100) 117 (81.3) 0.04
Hemi-thyroidectomy 27 (8.3) - 27 (18.7)
Lymph node surgery
Central neck dissection 88 (27.0) 54 (29.7) 34 (23.6)
Lateral neck dissection 18 (5.5) 9 (4.9) 9 (6.3) 0.9
Sampling 55 (16.9) 25 (13.7) 30 (20.8)
None 165 (50.6) 94 (51.7) 71 (49.3)
Mean size (cm) 0.61 (0.1–1.0) ± 0.24 0.72 (0.2–1.0) ± 0.21 0.44 (0.1–0.9) ± 0.2
≤0.5 cm 161 (49.4) 50 (27.5) 111 (77.1) <0.0001
≥0.5 cm 165 (50.6) 132 (72.5) 33 (22.9)
Histopathologic variants
Classic 265 (81.3) 143 (78.6) 122 (84.7)
Follicular 41 (12.6) 21 (11.5) 20 (13.9)
Hurthle cell 8 (2.5) 6 (3.3) 2 (1.4)
Tall cell 11 (3.4) 11 (6.0) - 0.001
Sclerosing 1 (0.3) 1 (0.5) -
Multifocal
Yes 125 (38.3) 122 (67.1) 3 (2.1) <0.0001
No 201 (61.7) 60 (32.9) 141 (97.9)
ETE
Yes 62 (19.0) 57 (31.3) 5 (3.5) <0.0001
No 264 (81.0) 125 (68.7) 139 (96.5)
LVSI
Yes 55 (16.9) 49 (26.9) 6 (4.2) <0.0001
No 271 (83.1) 133 (73.1) 138 (95.8)
Surgical margins
Positive 35 (10.7) 30 (16.5) 5 (3.5) <0.0001
Negative 291 (89.3) 152 (83.5) 139 (96.5)
Lymph node metastasis
Yes 42 (12.9) 42 (23.1) - <0.0001
N1a 34 (73.8) 34 (73.8)
N1b 8 (19.2) 8 (19.2)
No 284 (87.1) 140 (76.9) 144 (100)
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for tumors with multifocality and focal ETE (27.5 %);
100 mCi for tumors with multifocality, ETE, LVSI, posi-
tive surgical margins, poor histopathologic variants, and
elevated postoperative stimulated TG levels (>2 ng/ml)
(46.7 %); 150 mCi for positive lymph nodes (24.7 %), and
200 mCi for distant metastasis at the time of diagnosis
(1.65 %). RAI ablation was tolerated well without any
grade 3 or 4 side effects. Additional neck irradiation was
given in two patients with adherent tumors; trachea (one
patient; 0.5 %) and skeletal muscle (one patient; 0.5 %).
A median follow-up period was 8.05 years (range:
1.62–11.4). For whole cohort, the 5 and 10 years LRFS
were 98.4 % and 96.8 % respectively; DMFS rates were
92.4 % at 5 years and 90 % at 10 years. Five and 10 years
OS rates were 99.3 % and 98.6 % (two deaths) and the 5
and 10 years DFS rates were 94.7 % and 89.6 %.
Total 23 recurrences (7.13 %) were observed; 8/182 in
patients with RAI ablation and 15/144 in patients
without RAI ablation. The pattern of recurrences was as:
three patients had disease in thyroid bed only, 10 had
cervical nodes, and 10 failed at distant sites (9 patients
in lungs and one patient in bones). Combined locoregional
and distant recurrences were seen in 3 patients. The ele-
vated TG levels were always seen with local recurrences
and distant metastasis. The isolated locoregional recur-
rences were salvaged by surgery (lateral neck dissection; 7
patients, completion thyroidectomy; 2 patients and excision
in one patient), followed by RAI ablation (12 patients) and
distant failures were salvaged by RAI ablation (9 patients)
and palliative irradiation for bony lesion (one patient). Time
to initial local recurrence was 0.8 years and time to initial
distant metastasis was 1.5 year. The 5 and 10 year DFS
rates were 95.7 % vs. 90.9 % and 92.2 % vs. 84 % in patients
with and without RAI ablation respectively (p = 0.04) Fig. 1a.
The 5 and 10 year DFS rates according to different prog-
nostic factors are summarized in Table 2. The overall 5 and
10 year DFS rates were significantly dropped in the pres-
ence of poor histopathologic variants (p < 0.001) and ETE.
In addition to these factors, multifocality (p < 0.001) LVSI
(p = 0.001) and elevated postoperative thyroglobulin levels >
2 ng/ml (p = 0.04) resulted in inferior 5 and 10 year DFS in
patients treated without RAI ablation.
Table 1 Patients characteristics (Continued)
Background thyroid tissue
Normal 98 (30.1) 47 (25.8) 51 (35.4)
Multi-nodular goiter 106 (32.5) 60 (32.9) 46 (31.9)
Lymphocytic thyroiditis/Hashimotos’ thyroiditis 122 (37.5) 75 (41.3) 47 (32.6) 0.052
Distant Metastasis at presentation 3 (0.9) 3 (1.65) - <0.0001
AJCC staging
I 217 (66.5) 73 (40.1) 139 (96.5)
II - - -
III 96 (29.5) 96 (52.6) 5 (3.5) <0.0001
IVA 10 (3.1) 10 (5.6) -
IVB - - -
IVC 3 (0.9) 3 (1.7) -
Mean postoperative TG (ng/ml) 1.39 (0.1–42890) 2.44 (0.1–42890) 0.39 (0.1–8.9) 0.62
RAI dose
30 mCi 50 (27.5) - <0.0001
100 mCi 85 (46.7) -
150-200 mCi 47 (25.8) -
RT to Neck 2 (0.61) 2 (1.1) - <0.0001
Recurrences
Locoregional 13 (3.9) 4 (2.2) 9 (6.2) <0.001
Distant 10 (3.1) 4 (2.2) 6 (4.2)
*P value pertaining to the variation in clinicopathological characteristics between two groups
RAI radioactive iodine 131, N number, SD standard deviation, ETE extra-thyroidal extension, LVSI lymphovascular space invasion, AJCC American joint committee
on cancer, TG thyroglobulin, mCi millicurie, RT radiation therapy
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Clinicopathological features and DFS comparison among
PMC of size ≤ 0.5 cm and > 0.5 cm
With regard to the difference in DFS (locoregional and
distant failure), a comparative analysis was performed
according to primary tumor size (≤0.5 cm vs. > 0.5 cm)
as described in the Table 3. About 161 (49.4 %) patients
had tumors of size ≤ 0.5 cm and 165 (50.6 %) patients
had tumors of size above 0.5 cm in greatest dimension.
Significant demographic and clinicopathological differ-
ences were observed between two groups. Patients with
tumor size ≤ 0.5 cm were younger (mean age 36.7 years),
with higher female to male ratio (6.3), and with more
aggressive histopathologic variants (tall cell, sclerosing).
The cervical lymph node metastases were seen in 9.3 %
of patients with tumor size ≤ 0.5 cm as compared to
patients with tumor size > 0.5 cm (16.4 %) with p < 0.001.
Patients with tumor size ≤ 0.5 cm had high rates of hemi-
thyroidectomy (18.7 %), less adjuvant RAI ablation (31.1 %)
with low recurrence rates. There was also no significant
difference in 5 and 10 year DFS rates in in patients with
tumor size ≤ 0.5 cm treated with or without adjuvant RAI
ablation (p = 0.71) Fig. 1b. Further it was seen that adjuvant
RAI ablation did better in N0 as compared to N1 neck sta-
tus Fig. 1c. Also in patients treated with adjuvant RAI abla-
tion, no significant difference was observed between two
dose regimens (30 mCi vs. 100 mCi) with p = 0.62 (Fig. 1d).
Prognostic factors
Cox regression Model using univariate and multivariate
analysis for DFS to predict important prognostic factors
Fig. 1 Kaplan-Meier curves of disease free survival (a) according to treated with or without radioactive iodine 131 ablation, (b) primary size
(≤0.5 cm vs. > 0.5 cm) treated with or without radioactive iodine 131 ablation, (c) lymph node status and (d) dose regimens (30 mCi vs. 100 mCi)
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Table 4. Important prognostic factors were, histopatho-
logic variants (p < 0.0001), multifocality (p < 0.0001), ETE
(p < 0.0001), LVSI (p =0.03), nodal status (p < 0.0001), and
adjuvant RAI ablation (p < 0.0001).
Discussion
Despite excellent DFS rates in patients with PMC, about
3–16 % of patients develop local and distant failures
[11]. In present study, we were able to determine overall
five and ten year DFS rates of 94.7 % and 89.6 % respect-
ively after aggressive treatment by total thyroidectomy
followed by RAI ablation in the majority of cases. These
results were found in consistent with similar reported
data [12–15]. Several clinicopathological and treatments
related prognostic factors were observed. An important
prognostic factor, the age > 45 years was not found a
prognosticator to predict DFS in our study, suggesting
that other risk factors, such as aggressive histopathologic
variants, multifocality, ETE, and LVSI are more import-
ant clinicopathological predictors than age in PMC [16].
Similarly, in contrast to other reported data, gender was
also not found an important predictor of DFS [17].
Improved DFS was observed in patients who underwent
total thyroidectomy. Possible explanation for this could
be (a) high percentage of multifocality, and (b) more
aggressive histopathological variants (tall cell and diffuse
Table 2 Disease free survival according to different prognostic factors
Variable RAI ablation Without RAI ablation
5 years-DFS p 10 years-DFS p 5 years-DFS p 10 years-DFS p
Age
≤45 years 97.8 % 93.5 % 87.6 % 83.6 %
≥45 years 92.5 % NS 85.3 % NS 88.5 % NS 84.5 % NS
Gender
Female 95.4 % 91.2 % 93.8 % 82.2 %
Male 96.8 % NS 89.4 % NS 90.4 % NS 82.0 % NS
Histopathologic variants
Classic 96.1 % 93.5 % 95.5 % 92.3 %
Follicular 94.7 % 90.9 % 78.9 % 59.6 %
Hurthle cell 96.1 % 92.7 % 90.0 % 0.001 78.9 % <0.001
Tall cell 68.2 % - -
Sclerosing 55.0 % 0.002 - <0.001 -
Multifocal
Yes 95.2 % 90.9 % 66.7 % 33.3 %
No 96.6 % NS 93.4 % NS 90.0 % <0.001 88.3 % <0.0001
Surgical margins
Positive 96.6 % 91.5 % 86.3 % 84.0 %
Negative 96.8 % NS 95.3 % NS 93.2 % NS 87.9 % NS
ETE
Yes 89.5 % 85.5 % 40.0 % 0.0 %
No 98.2 % 0.03 95.1 % 0.02 91.7 % <0.0001 80.1 % <0.0001
LVSI
Yes 89.5 % 85.5 % 80.0 % 60.0 %
No 92.5 % NS 89.4 % NS 93.2 % 0.02 84.4 % 0.001
Mean postoperative TG
≤2 ng/ml 96.6 % 93.4 % 93.2 % 91.7 %
>2 ng/ml 89.5 % NS 85.5 % NS 87.9 % NS 80.1 % 0.04
Surgery
Total thyroidectomy 96.0 % 94.4 % 93.2 % 87.5 %
Hemi-thyroidectomy 91.5 % 0.03 86.0 % 0.03 85.1 % 0.04 80.2 % 0.02
RAI radioactive iodine 131, yr year, DFS disease free survival, SD standard deviation, ETE extra-thyroidal extension, LVSI lymphovascular space invasion,
TG thyroglobulin
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Table 3 Comparative analysis of clinicopathological characteristics based on the size of primary tumors
Variable Tumor size ≤ 0.5 cm N (%) Tumor size > 0.5 cm N (%) P value
Total patients 161/326 (49.4) 165/326 (50.6) -
Age (years) 36.7 (8–71) 47.8 (8–76)
≤45 years 107 (66.5) 94 (56.9) 0.034
≥45 years 54 (33.5) 71 (43.1)
Gender
Female 139 (86.4) 132 (80.0) 0.08
Male 22 (13.6) 33 (20.0)
Mean size (cm) 0.38 (0.1–0.5) 0.68 (0.6–1.0) <0.001
Histopathologic variants
Classic 126 (78.2) 139 (84.3)
Follicular 26 (16.2) 14 (8.5)
Hurthle cell 4 (2.5) 4 (2.4) 0.023
Tall cell 4 (2.5) 7 (4.3)
Sclerosing 1 (0.6) -
Multifocal
Yes 36 (22.4) 89 (53.9)
No 125 (77.6) 76 (46.1) <0.001
ETE
Yes 16 (9.9) 46 (27.9) <0.001
No 145 (90.1) 119 (72.1)
LVSI
Yes 14 (8.7) 41 (24.9) <0.001
No 147 (91.3) 124 (75.1)
Surgical margins
Positive 5 (3.1) 30 (18.2)
Negative 156 (96.9) 135 (81.8) <0.001
Background thyroid tissue
Normal 60 (37.3) 38 (23.0)
Multi-nodular goiter 48 (29.8) 58 (35.2)
Lymphocytic thyroiditis/Hashimotos’ thyroiditis 53 (32.9) 69 (41.8) 0.05
Lymph node metastasis
Yes 15 (9.3) 27 (16.4)
No 146 (90.7) 138 (83.6) <0.001
RAI ablation
Yes 50 (31.1) 132 (67.3) <0.001
No 111 (68.9) 22 (13.3)
Recurrences
Locoregional 4 (2.5) 9 (5.5)
Thyroid bed 1/4 2/9
Lymph nodes 3/4 7/9 <0.001
Distant 2 (1.3) 8 (4.9)
Lungs 2 7/8
Bone - 1/8
I-131 radioactive iodine 131, N number, ETE extra-thyroidal extension, LVSI lymphovascular space invasion, RAI radioactive iodine
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sclerosing variants) in our series, which is in agreement
with few previously published studies of PMC [18–20].
Recent studies regarding PMC have reported that pa-
tients with multinodular goiter (MNG) and with lympho-
cytic or Hashimotos’ thyroiditis are associated with better
prognosis; however, we could not reproduce the same re-
sults. Reason could be (a) few cases of histopathological
proven MNG (32.5 %); (b) lack of preoperative TFTs in
MNG patients; and (c) few number of patients with
lymphocytic/Hashimoto’s thyroiditis (37.5 %) [21].
Further, present study showed the lymph node involve-
ment and tumor size as the most significant independent
risk factors for recurrence. Although we found tumor
size > 0.5 cm seem to be associated with high recurrence
rates, we were not able to identify a size threshold below
which there was no lymph node involvement and no
risk of recurrence; as in tumor of size ≤ 0.5 cm, 9.3 %
lymph node metastasis were seen along with 2.5 % local
and 1.3 % distant failures. This supports the hypothesis,
that lymph node involvement status is higher in PMC
of size > 0.8 cm, but is independent of tumor size [22].
Patients tolerated adjuvant RAI ablation very well with
minimal toxicity. Failure of RAI ablation to decrease
local or distant failure risk in N1a/b as compared to N0
disease is an indicator of underlying tumor burden in
neck and this supports the idea of prophylactic central
neck dissection during thyroidectomy [23]. However,
still there is much debate over the prophylactic central
neck dissection because of potential increased risk of
hypoparathyroidism associated with central neck dis-
section [24].
Strengths of our study were; (a) reasonable sample size
of Saudi patients with PMC, and (b) long term follow up
period. Limitations of our study were; (a) retrospective
data; (b) no intention to treat based analysis, and (c) lack
of availability of preoperative clinical data, diagnostic
methods (FNAC and radiology), tumor characteristics
and baseline TFTs.
Conclusions
In conclusion, among all PTC, 31.6 % of patients are
diagnosed as PMC. Despite excellent DFS rates, a small
proportion of patients with PMC develop recurrences
after treatment. These recurrences not only badly affect
physical health, but also mental and social health and
overall quality of life. Based on our results we conclude
that;
 High percentage of multifocality in our population
of PMC favors near total or total thyroidectomy
against lobectomy, which can be an option for
unifocal PMC.
 Age > 45 years and gender were not found strong
prognostic factors of DFS.
 Adjuvant RAI therapy improves DFS in PMC
patients with aggressive histopathologic variants,
multifocality, ETE, LVSI, tumor size (>0.5 cm in
absence of other features) and lymph node
involvement (≥150 mCi). In absence of N0 neck,
there is significant difference of DFS in two doses
(30 mCi vs. 100 mCi).
Table 4 Cox regression model of various prognostic factors for
disease specific survival
Variable All patients
Univariate analysis Multivariate analysis
RR (95 % CI) p RR (95 % CI) p
Age
≤45 years 1.05 (0.7–1.3) 1.07 (0.8–1.3)
≥45 years 1.10 (0.8–1.4) 0.6 1.10 (0.9–1.3) 0.06
Gender
Female 1.07 (0.9–1.4) 1.05 (0.7–1.3)
Male 1.05 (0.7–1.3) 0.6 1.40 (1.2–1.6) 0.05
Histopathologic variants
Classic 1.05 (0.7–1.2) 1.20 (0.8–1.6)
Follicular 1.00 (0.6–1.8) 1.18 (0.7–1.5)
Hurthle cell 1.30 (1.1–1.7) 2.00 (1.6–2.4)
Tall cell 2.70 (1.6–4.5) 2.82 (2.4–4.6)
Sclerosing 1.80 (1.6–2.9) <0.0001 2.00 (1.6–3.0) <0.0001
Multifocal
Yes 3.1 (2.8–4.2) 2.94 (2.2–3.4)
No 1.0 (0.8–1.2) <0.0001 1.07 (0.9–1.3) <0.0001
Surgical margins
Positive 1.10 (0.9–1.4) 1.20 (0.8–1.6)
Negative 1.07 (0.9–1.4) 0.7 1.17 (0.6–1.2) 0.68
ETE
Yes 4.2 (3.5–5.1) 3.31 (1.7–4.2)
No 1.05 (0.7–1.1) <0.0001 1.17 (0.9–1.4) <0.0001
LVSI
Yes 2.0 (1.7–2.9) 1.81 (1.6–2.8)
No 1.0 (0.8–1.2) 0.02 1.04 (0.9–1.5) 0.03
Lymph nodes
Positive 4.45 (3.7–6.8) 3.74 (3.4–5.9)
Negative 1.17 (0.9–1.4) <0.0001 1.01 (0.8–1.3) <0.0001
Mean postoperative TG
≤2 ng/ml 1.01 (0.7–1.2) 1.05 (0.7–1.2)
>2 ng/ml 1.04 (0.9–1.5) 0.6 1.00 (0.6–1.8) 0.6
RAI ablation
Yes 0.35 (0.2–0.7) 0.30 (0.2–0.8)
No 1.09 (1.0–1.9) <0.0001 1.00 (0.6–1.8) <0.0001
I-131 radioactive iodine 131, RR relative risk, CI confidence interval, ETE extra-
thyroidal extension, LVSI lymphovascular space invasion, TG thyroglobulin, RAI
radioactive iodine
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 Failure of RAI ablation to decrease risk in N1a/b
supports prophylactic central neck dissection during
thyroidectomy, however more trials are warranted.
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